Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: A review of the literature

Research output: Contribution to journalReview article

Abstract

Male breast cancer (MaBC) is a rare disease, accounting for less than 1% of malignancies in men. For this reason, literature data on its clinicopathological characteristics are very heterogeneous and treatment strategies have mostly been extrapolated from the female counterpart. However, immunohistochemical peculiarities of MaBC have recently emerged, defining it as a distinct entity from female breast cancer (FBC), thus requiring a tailored clinical approach. MaBC appears to be more often hormone receptor positive than FBC, while data on HER2 status still remain inconclusive, indicating a possible higher incidence of HER2 alterations. Treatment strategies for MaBC have evolved and less invasive local treatments such as lumpectomy and sentinel lymph node biopsy have become part of everyday clinical practice, while there are still controversies on the indication of radiotherapy, especially after mastectomy. Similarly, differences between male and female hormonal status have raised some concerns in the use of aromatase inhibitors in male patients and the choice of best endocrine therapy is still controversial.

Original languageEnglish
Pages (from-to)283-291
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume113
DOIs
Publication statusPublished - May 1 2017

Keywords

  • Aromatase inhibitors
  • Estrogen and progesterone receptors
  • Fulvestrant
  • HER2
  • Ki-67
  • Male breast cancer
  • Tamoxifen

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: A review of the literature'. Together they form a unique fingerprint.

  • Cite this